S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

3 Small-Cap Stocks For Your Fall Shopping List

Wednesday, September 29, 2021 | Chris Markoch
3 Small-Cap Stocks For Your Fall Shopping List

Small-cap stocks are loosely defined as companies with a market capitalization of less than $2 billion dollars. When they are compared to large- and mid-cap companies, small-cap stocks are typically seen as having better growth potential.

By nature, small-cap stocks are subject to volatile price swings that make them appropriate only for risk-tolerant investors. One such risk is that many small-cap companies are newer entries into their field. And depending on where they are in their business cycle, they may require access to a lot of capital which can be hard to acquire.

However, if you have a tolerance for risk, these stocks have the potential for gains that exceed that of the broader market. Like any asset class, doing your due diligence is a necessity. This is another good reason to become a MarketBeat All Access member. You’ll get access to features such as a list of the Top-Rated Small-Cap Stocks. With that in mind, here are three stocks for you to add to your watch list.

Purple Innovation (NASDAQ: PRPL) – For obvious reasons, PRPL stock did very well during the pandemic. Many people sought to improve the quality of their homes and health. And, for many, this meant buying Purple Innovation’s products to make their home more comfortable. Revenue was up 51% in 2020 and earnings per share were up 80% as compared to 2019.

But you shouldn’t dismiss Purple Innovation as being just a pandemic play. For the first half of 2021, revenue is on pace to be higher than 2020 although earnings look to be lower. That could be weighing on the stock which is trading near its 52-week lows. Plus, one analyst just downgraded the stock. However, the consensus price target of analysts has PRPL stock trading at around $35 per share.

ThredUp (NASDAQ: TDUP) – The next small-cap stock that should be on your watch list is ThredUp. This is an online consignment store that has been in business since 2009. TDUP has only been trading publicly since March 2021. In that time, the stock has shown plenty of volatility and is undoubtedly frustrating investors because it’s trading right around its initial public offering (IPO) price.

But with small-cap stocks, it’s less about where the stock has been then about where it’s going. In this case, analysts are giving TDUP stock a $26 price target. If I was to be concerned about anything, it’s that the stock has a high short percentage of float. That means that it will be popular with short-term traders who are looking to capitalize on a short-term trade. But with inflation and supply chain challenges likely to be around for several quarters, shopping secondhand has never looked thriftier.

Taysha Gene Therapies (NASDAQ: TSHA) – The last of the small-cap stocks on this list is the one with the most risk, but also the greatest potential upside. The field of gene therapy will be one of the hottest fields of biotechnology in the next decade. Taysha Gene Therapies is focused on eradicating monogenic diseases of the central nervous system. Monogenic disorders are caused by variation in a single gene.

Many biotech companies are pre-revenue companies which means the pipeline is critical. And Taysha currently has 26 Adeno-Associated Virus (AAV)-based gene therapies under development. Several of these candidates are approaching critical stages that could lead to them making it through the clinical trial stage.

At this time, analysts have a price target of over $44 for TSHA stock. Short interest remains a little high, but that’s not unusual for small-cap stocks.

Should you invest $1,000 in Taysha Gene Therapies right now?

Before you consider Taysha Gene Therapies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.

While Taysha Gene Therapies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Taysha Gene Therapies (TSHA)2.5$12.45-4.9%N/AN/ABuy$46.45
ThredUp (TDUP)2.2$15.24-1.9%N/AN/ABuy$27.09
Purple Innovation (PRPL)2.5$9.69-5.2%N/A161.50Hold$21.27
Compare These Stocks  Add These Stocks to My Watchlist 

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.